secwatch.observer — SEC 8-K summary
======================================

Issuer:     THERMO FISHER SCIENTIFIC INC. (TMO)
CIK:        0000097745
Form:       8-K
Filed at:   2026-07-23T10:04:03+00:00
Accession:  0000097745-26-000138
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Thermo Fisher Q2 revenue $11.99B (+10%), GAAP EPS $4.68 (+9%), adjusted EPS $6.03 (+13%)
--------------------------------------------------------------------------------

- Organic revenue growth of 5%; GAAP operating margin 17.4% vs 16.9% YoY; adjusted operating margin 22.8% vs 21.9%.
- Announced divestiture of microbiology business and repurchased $1.0B of stock during the quarter.
- Launched new Orbitrap mass spectrometers with AI analytics and PowerFlex thermal cycler; opened U.S. Bioprocess Design Center.
- Strategic collaboration with Precision Health Research, Singapore for PRECISE-SG100K population health study using Olink technology.
- Company to provide updated 2026 financial guidance on earnings call at 8:30 a.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/97745/000009774526000138/0000097745-26-000138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/97745/000009774526000138/tmo-20260723.htm
  HTML page:      https://secwatch.observer/filing/0000097745-26-000138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer